Cantargia announces appointment of Patrik Renblad as Chief Financial Officer
Cantargia (Cantargia AB; Nasdaq Stockholm: CANTA), a clinical-stage biotech company focused on antibody-based therapies targeting IL1RAP for cancer and inflammatory diseases, today announced it has appointed Patrik Renblad as its new Chief Financial Officer (CFO). Mr Renblad will assume this role by August 2023, at the latest.“I am delighted to welcome Patrik Renblad as Cantargia’s new CFO. Patrik brings a wealth of experience gained from an international career with leading positions in both pharma and biotech, which will be important to Cantargia in the next stage of the company’s